The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Definitive chemoradiotherapy for locoregional recurrence of esophageal squamous cell carcinoma patients after radical surgery: Retrospective study.
 
Kentaro Harada
No Relationships to Disclose
 
Shun Yamamoto
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical
 
Akihiro Ohara
No Relationships to Disclose
 
Mai Itoyama
No Relationships to Disclose
 
Yoshitaka Honma
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai/Roche; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Teijin Pharma
Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Loxo (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Rakuten Medical (Inst); Taiho Pharmaceutical (Inst)
 
Tairo Kashihara
Honoraria - AstraZeneca
 
Koji Inaba
Honoraria - Boston Scientific
 
Koshiro Ishiyama
No Relationships to Disclose
 
Junya Oguma
No Relationships to Disclose
 
Hiroshi Igaki
Honoraria - Himedic; Itochu; Varian Medical Systems
Consulting or Advisory Role - HekaBio
Research Funding - Children's Integrated Center for Success; Elekta; HekaBio
 
Hiroyuki Daiko
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)